IMO the control arm has evented and we are not looking at a control arm MOS of 13-15 months
Well, Geo, it would be nice if you're correct.
:-)
Another question: what's to keep the folks in our 1st line trial who haven't responded to treatment, either in the control arm or the treatment arm, from leaving this trial and entering a 2nd line trial? If they do go somewhere else, does this skew our results?
Market Data 
Markets 
AI
